Results 241 to 250 of about 166,181 (302)

Subacute cutaneous lupus erythematosus

2000
Subacute cutaneous lupus erythematosus (SCLE) represents a relatively distinct and homogeneous subset of lupus erythematosus (LE) identified by chronic and recurrent development of characteristic erythematous, non-scarring and mostly photosensitive skin lesions associated with particular clinical, immunological and genetic features.
M. N. Manoussakis, H. M. Moutsopoulos
openaire   +1 more source

Therapy of Cutaneous Lupus Erythematosus

Medical Clinics of North America, 1982
Cutaneous lupus erythematosus occurs in a spectrum from limited cutaneous disease to severe systemic disease. Chronic DLE generally follows a benign course, but rare transformation to systemic disease may occur. Subacute cutaneous LE is associated with a specific cutaneous lesion and mild to moderate systemic symptoms.
openaire   +2 more sources

Investigating the presence of neutrophil extracellular traps in cutaneous lesions of different subtypes of lupus erythematosus

Experimental Dermatology, 2019
Neutrophil extracellular traps (NETs) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). However, little is known about the implication of NETs in cutaneous lupus.
R. Safi, J. Al-Hage, O. Abbas, A. Kibbi, Dany Nassar   +4 more
semanticscholar   +1 more source

Treatment of cutaneous lupus erythematosus

Lupus, 2010
In patients with cutaneous lupus erythematosus (CLE) and mild skin involvement, local therapy consisting of topically applied pharmacological agents, e.g., topical/intralesional steroids, may be sufficient. Recent reports have also shown efficacy of topical calcineurin inhibitors in patients with CLE, particularly on the face.
A, Kuhn, F, Ochsendorf, G, Bonsmann
openaire   +2 more sources

Cutaneous lupus erythematosus induced by drugs - novel insights

Expert Review of Clinical Pharmacology, 2019
Introduction: There is a growing list of drugs implicated in inducing both subacute and chronic forms of cutaneous lupus erythematosus. It is important to recognize these drugs in order to quickly treat patients with drug induced disease.
R. Borucki, V. Werth
semanticscholar   +1 more source

Cutaneous Lupus Erythematosus Patients With a Negative Antinuclear Antibody Meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics Criteria for Systemic Lupus Erythematosus

Arthritis care & research, 2019
Systemic lupus erythematosus (SLE) is a disorder that is heterogeneous and can be difficult to diagnose. One hallmark of the disease is the presence of antinuclear antibodies (ANAs), a feature that has been incorporated into multiple classification ...
M. Tarazi, R. Gaffney, C. Kushner, S. Chakka, V. Werth   +4 more
semanticscholar   +1 more source

Bullous subacute cutaneous lupus erythematosus

Clinical and Experimental Dermatology, 2004
We describe a 59-year-old woman, with a history of autoimmune disease and disseminated uterine leiomyosarcoma, who developed a photoaggravated, blistering skin eruption. An initial rash, at the outset of treatment with chemo- and radiotherapy, resembled erythema multiforme.
Perera, G K, Black, M M, McGibbon, D H
openaire   +3 more sources

Thalidomide in Cutaneous Lupus Erythematosus

American Journal of Clinical Dermatology, 2003
For nearly 50 years, thalidomide has struggled between success and controversy. After causing an epidemic of phocomelia and other birth defects during the 1960s, affecting thousands of neonates, thalidomide was used as a sedative in selective disorders including leprosy.
Michelle T, Pelle, Victoria P, Werth
openaire   +2 more sources

Poikilodermatous Subacute Cutaneous Lupus erythematosus

Dermatology, 2003
<i>Background:</i> Subacute cutaneous lupus erythematosus (SCLE) is a distinct subset of lupus erythematosus with unique clinical, immunological and genetic features. Among the unusual variants of SCLE, there is a poikilodermic presentation. However, to date, only 1 case of poikilodermatous SCLE has been reported.
Angelo V, Marzano, Maura, Facchetti, Elvio, Alessi   +2 more
openaire   +2 more sources

Pathogenesis of cutaneous lupus erythematosus

Clinics in Dermatology, 1985
Antibody-dependent mechanisms of tissue damage are the principle mechanism of disease in systemic and cutaneous lupus erythematosus. Antibody-dependent mechanisms of keratinocyte damage appear to be a primary pathogenetic factor in all forms of papulosquamous cutaneous lupus. Photosensitive papulosquamous lupus syndromes, such as subacute cutaneous LE,
D A, Norris, L A, Lee
openaire   +2 more sources